Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: Preliminary experience

S. M. Larson, J. A. Carrasquillo, R. W. McGuffin, K. A. Krohn, J. M. Ferens, L. D. Hill, P. L. Beaumier, J. C. Reynolds, K. E. Hellström, I. Hellström

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


High molecular weight antigen (HMWA) is a tumor-associated proteoglycan of human malignant melanoma. I-131 labeled Fab fragments of these specific antibodies were used for preliminary feasibility studies for radioimmunodetection and therapy of human subjects who had inoperable metastatic melanoma. Ten patients received tracer doses of 5-13 mCi (185-481 MBq) of I-131 (anti-HMWA) Fab. All patients (8/8) who had melanoma lesions greater than 1 cm by correlative diagnostic methods had one or more lesions that had localization to tumor of the radiolabeled Fab. In all, 17 of 23 (74%) documented metastases were seen. There were no false positives in this series. Two patients who had avid uptake received potentially radiotherapeutic doses of 142 mCi (5,254 MBq) (one patient) and 181 mCi (6,697 MBq) and 193 (7,141 MBq) (total: 374 mCi or 13,838 MBq) (one patient). For both of these patients, whole body imaging studies showed that the localization of the high dose I-131 Fab was predominantly in tumor. The patient who received the larger dose showed a greater than 50% reduction in the size of pelvic and pericaval nodes, with stabilization of disease at the smaller nodal size for a period of three months. On whole body images, the anti-Fab HMWA appears to be more tumor selective than Fab preparations that target the p97 antigen for melanoma, and there is less uptake in liver.

Original languageEnglish (US)
Pages (from-to)487-492
Number of pages6
Issue number2
StatePublished - 1985
Externally publishedYes

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: Preliminary experience'. Together they form a unique fingerprint.

Cite this